Table 2

Concentrations (pg/ml) of cytokines (pg/ml) secreted in vitro by rEBV-stimulated immune splenocytes isolated from nonvaccinated mice versus mice vaccinated with rEBV plus CpG and sacrificed at 7 days postchallengea

Secreted cytokineIn vitro stimulation of immune splenocytes from mice in indicated group
Growth medium alonerEBV
1 μg/ml10 μg/ml
NonvaccinatedVaccinatedNonvaccinatedVaccinatedNonvaccinatedVaccinated
Proinflammatory
    IL-65.9 ± 2.944.2 ± 2.9*281.3 ± 7.52,225.0 ± 130.9*814.3 ± 49.22,042.0 ± 152.7*
    IL-17A4.9 ± 0.423.8 ± 2.2*28.2 ± 0.9273.5 ± 13.6*23.2 ± 4.8325.9 ± 13.2*
Regulatory
    IL-109.0 ± 0.834.8 ± 3.6*55.4 ± 4.1233.8 ± 14.9*221.6 ± 10.9769.9 ± 18.6*
Th1 type
    IL-297.0 ± 8.6176.4 ± 10.3*185.4 ± 5.62,101.3 ± 45.6*97.2 ± 2.94,195.6 ± 142.5*
    IFN-γ7.8 ± 2.08.6 ± 1.660.5 ± 7.83,035.0 ± 95.7*71.4 ± 6.62,531.0 ± 188.8*
Th2 type
    IL-44.5 ± 0.713.0 ± 0.2*5.4 ± 0.215.3 ± 0.9*3.6 ± 0.134.0 ± 0.2*
    IL-52.1 ± 0.647.5 ± 0.9*10.5 ± 1.4214.5 ± 6.8*9.8 ± 0.8166.3 ± 7.5*
  • a rEBV, recombinant vaccine protein was added to immune cells in growth medium and the mixture was incubated for 48 h. Nonvaccinated mice were immunized with CpG alone. Asterisks indicate a significant difference between cytokine concentrations (P < 0.05) in culture supernatants of in vitro stimulated immune splenocytes derived from nonvaccinated mice versus mice vaccinated with rEBV plus CpG.